202.95
+10.73%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About IOL Chemicals and Pharmaceuticals
Its shares trade on NSE under the ticker IOLCP.NS. It has been listed since 5 November 2010. In the fiscal year to 31 March 2026, it reported revenue of ₹23.19bn and net income of ₹1.38bn. At that date it held total assets of ₹25.87bn and shareholders' equity of ₹17.99bn.
IOL Chemicals & Pharmaceuticals Ltd. engages in the manufacture of organic and inorganic chemical compounds. The company is headquartered in Ludhiana, Punjab. The company went IPO on 2010-11-05. The firm's APIs portfolio covers various therapeutic categories, such as pain management, anti-diabetic, anti-hypertensive, and anti-convulsant, amongst others. The firm operates through two business divisions: Active Pharma Ingredients (API), and Specialty Chemicals. Its API vertical is engaged in research, developing, and providing various essential products that are used by pharma companies. Its API product portfolio includes Ibuprofen, Ibuprofen Lysinate, Ibuprofen Sodium, Dex-Ibuprofen, Metformin HCL, Clopidogrel Bisulphate (Form II), Pantoprazole Sodium, Fenofibrate, Gabapentin, Lamotrigine, Ursodeoxycholic Acid, Losartan Potassium and Levetiracetam. Its Specialty Chemical division includes Ethyl Acetate, Iso Butyl Benzene, Acetyl Chloride and Mono Chloro Acetic Acid.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 5 Nov 2010
- Employees
- 2,557
- Website
- iolcp.com ↗
Leadership
Pay as last reported
- Mr. Rajender MallaIndependent Chairman of the Board₹450,000
- Mr. Pardeep KhannaChief Financial Officer
- Mr. Abhay SinghSenior Vice President, Company Secretary
- Mr. Varinder GuptaManaging Director, Executive Director, since 2021₹104.0m
- Mr. Vikas GuptaJoint Managing Director, Executive Director, since 2015₹31.8m
- Mr. Abhiraj GuptaExecutive Director, since 2023₹14.4m
- Mr. Kushal RanaDirector - Works, Executive Director, since 2021₹18.1m
- Ms. Rajni JhaIndependent Director₹200,000
- Mr. Harpal SinghIndependent Director₹950,000
- Mr. Sharad TyagiIndependent Director₹1.3m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- IOL Chemicals & Pharmaceuticals Ltd. manufactures Ibuprofen and Metformin HCL for pain management and anti-diabetic therapies.
- The company's API division provides essential products like Pantoprazole Sodium and Fenofibrate for pharma companies.
- IOL's Specialty Chemicals division produces Ethyl Acetate and Acetyl Chloride for industrial applications.
Weaknesses
- IOL Chemicals & Pharmaceuticals Ltd. has no presence in the Financials or Real Estate sectors.
- The company's API portfolio lacks products for anti-hypertensive and anti-convulsant therapies.
- IOL's Specialty Chemicals division does not include Mono Chloro Acetic Acid in its product range.
Opportunities
- IOL can expand its API portfolio to include anti-hypertensive and anti-convulsant therapies.
- The company can leverage its existing API products for new markets in India and globally.
- IOL's Specialty Chemicals division can target new industrial applications for Ethyl Acetate.
Threats
- IOL Chemicals & Pharmaceuticals Ltd. faces competition from other API manufacturers in the Indian market.
- The company's reliance on a limited number of API products poses a risk to its revenue streams.
- IOL's Specialty Chemicals division may face regulatory challenges in international markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.